Swiss Cancer Institute

This study tests whether adding darolutamide to standard treatments can help men with a certain type of advanced prostate cancer (mCRPC) live longer without their cancer getting worse. About 162 participants will receive either standard care alone or standard care plus darolutami…

This study is for people aged 70 and older with advanced non-small cell lung cancer who are too frail for standard chemotherapy. It compares a lower-dose chemo plus an immunotherapy drug (cemiplimab) against immunotherapy alone. The goal is to find a treatment that works well but…

This phase 2 trial tests whether injecting the experimental drug INT230-6 directly into the tumor before standard chemotherapy and immunotherapy can improve outcomes for people with early triple-negative breast cancer (TNBC). About 61 participants will be randomly assigned to rec…

This phase II trial is testing whether terbinafine, a widely used antifungal pill, can slow the rise of PSA in men whose prostate cancer has returned after initial treatment. The goal is to see if this well-tolerated drug can delay or replace standard hormone therapy, which often…

This study looks at people with advanced stage IV non-small cell lung cancer that has spread. After standard therapy (chemo, immunotherapy, or targeted drugs) works well, some will also get surgery or radiation on remaining tumors. The goal is to see if this extra treatment helps…

This study tests whether adding heat therapy to chemotherapy, radiation, and surgery is feasible for people with high-risk soft tissue sarcoma of the arms, legs, or trunk. About 24 participants will receive all treatments before surgery. The goal is to see if most patients can co…

This study is for people with early-stage ER+/HER2- breast cancer. It tests whether adding doxycycline, a safe and inexpensive antibiotic, to standard chemotherapy can better target cancer stem cells—cells that may cause the cancer to come back. About 50 participants will receive…

This study looks at why a specific type of advanced colorectal cancer (with a BRAF V600E mutation) becomes resistant to standard targeted therapy. Researchers will collect tumor tissue, blood, and stool samples from 30 patients before treatment and when the disease progresses. Th…